| 标题 |
A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension
一项比较贝伐单抗单药治疗与达卡巴嗪（DTIC）治疗恶性黑色素瘤的随机II期试验，重点关注血管生成标志物和高血压的预防
|
| 网址 | |
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | 摘要Brief Summary The purpose of this study is to compare efficacy of bevacizumab monotherapy with standard chemotherapy (DTIC) in patients with metastatic malignant melanoma. In addition, we want to evaluate the predictive value of a set biomarkers associated with vascular endothelial growth factor (VEGF) dependent angiogenesis. Also, we aim to identify mechanisms causing acquired resistance to treatment with bevacizumab and escape mechanisms caused by other angiogenic growth factors than VEGF. Finally, we want to analyze safety and influence on outcome variables by primary prevention of bevacizumab induced hypertension by low dose beta blockers in comparison with an ACE inhibitor. |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)
贪玩的秋柔
GingerF
云飞扬
Singularity
loii
大力的灵雁
OsamaKareem
strike
皖公网安备34019202002308
